Dr. Gearóid Tuohy

Swiss study concludes a modest clinical superiority of aflibercept (2 mg) and ranibizumab (0.5 mg) over other anti-VEGF formulations and dosages

Researchers based at the Cantonal Hospital of Lucerne, Switzerland have published research findings suggesting a modest superiority of aflibercept (2 mg) and ranibizumab (0.5 mg)… Read More »Swiss study concludes a modest clinical superiority of aflibercept (2 mg) and ranibizumab (0.5 mg) over other anti-VEGF formulations and dosages